We therefore recommend that perfusion imaging should be routinely incorporated into trials of agents targeting tumour vasculature as a biomarker of antiangiogenic activity and techniques such as 18F-FDG-PET should also be considered for early clinical trials of inhibitors of specific pathways, such as PI3K/AKT/MTOR. The gene discussed is MTOR; the disease is neoplasm.